ATE421880T1 - Die verwendung von 4-pyridylmethylphthalazinen zur behandlung von nierentumoren - Google Patents

Die verwendung von 4-pyridylmethylphthalazinen zur behandlung von nierentumoren

Info

Publication number
ATE421880T1
ATE421880T1 AT06114903T AT06114903T ATE421880T1 AT E421880 T1 ATE421880 T1 AT E421880T1 AT 06114903 T AT06114903 T AT 06114903T AT 06114903 T AT06114903 T AT 06114903T AT E421880 T1 ATE421880 T1 AT E421880T1
Authority
AT
Austria
Prior art keywords
pyridylmethylphthalazine
treatment
kidney tumors
phthalazine
pyridylmethyl
Prior art date
Application number
AT06114903T
Other languages
English (en)
Inventor
Margaret Han Dugan
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE421880T1 publication Critical patent/ATE421880T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06114903T 2001-09-12 2002-09-11 Die verwendung von 4-pyridylmethylphthalazinen zur behandlung von nierentumoren ATE421880T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33102501P 2001-09-12 2001-09-12
US31869401P 2001-09-12 2001-09-12
US32204401P 2001-09-14 2001-09-14
US38816302P 2002-06-12 2002-06-12

Publications (1)

Publication Number Publication Date
ATE421880T1 true ATE421880T1 (de) 2009-02-15

Family

ID=27502161

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06114903T ATE421880T1 (de) 2001-09-12 2002-09-11 Die verwendung von 4-pyridylmethylphthalazinen zur behandlung von nierentumoren
AT02779338T ATE329597T1 (de) 2001-09-12 2002-09-11 Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02779338T ATE329597T1 (de) 2001-09-12 2002-09-11 Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren

Country Status (22)

Country Link
US (2) US20040258770A1 (de)
EP (1) EP1427420B1 (de)
JP (1) JP2005502690A (de)
KR (1) KR20040029172A (de)
CN (1) CN1330308C (de)
AT (2) ATE421880T1 (de)
AU (2) AU2002342678B2 (de)
BR (1) BR0212446A (de)
CA (1) CA2457848A1 (de)
CO (1) CO5560545A2 (de)
CY (1) CY1105189T1 (de)
DE (2) DE60231068D1 (de)
DK (1) DK1427420T3 (de)
ES (2) ES2320922T3 (de)
HR (1) HRP20040241A2 (de)
IL (1) IL160382A0 (de)
NO (1) NO327358B1 (de)
NZ (1) NZ531484A (de)
PL (1) PL367349A1 (de)
PT (1) PT1427420E (de)
RS (1) RS16804A (de)
WO (1) WO2003022282A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
JP2006514991A (ja) * 2002-12-27 2006-05-18 シエーリング アクチエンゲゼルシャフト 新規医薬組合せ
EP1631278A4 (de) * 2003-05-20 2006-09-20 Aronex Pharmaceuticals Inc Kombinationschemotherapie mit capecitabin und einem liposomalen platinkomplex
CA2537991A1 (en) * 2003-09-23 2005-03-31 Novartis Ag Combination of a vegf receptor inhibitor with a chemotherapeutic agent
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
KR101037292B1 (ko) * 2010-09-03 2011-05-27 (주)슈추어 신발 장식구

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100189865B1 (ko) * 1994-08-09 1999-06-01 나이또 하루오 축합 피리다진계 화합물
DK0885198T3 (da) * 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
US6096904A (en) * 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion

Also Published As

Publication number Publication date
CA2457848A1 (en) 2003-03-20
US20040258770A1 (en) 2004-12-23
AU2006203428A1 (en) 2006-08-31
JP2005502690A (ja) 2005-01-27
CY1105189T1 (el) 2010-03-03
NZ531484A (en) 2007-02-23
RS16804A (en) 2007-02-05
AU2002342678B2 (en) 2006-08-24
BR0212446A (pt) 2004-08-17
IL160382A0 (en) 2004-07-25
HRP20040241A2 (en) 2005-04-30
WO2003022282A1 (en) 2003-03-20
PL367349A1 (en) 2005-02-21
ES2320922T3 (es) 2009-05-29
US20090196871A1 (en) 2009-08-06
CO5560545A2 (es) 2005-09-30
EP1427420A1 (de) 2004-06-16
EP1427420B1 (de) 2006-06-14
DE60212415T2 (de) 2006-11-23
DK1427420T3 (da) 2006-10-02
NO20040973L (no) 2004-06-03
CN1553803A (zh) 2004-12-08
KR20040029172A (ko) 2004-04-03
DE60212415D1 (de) 2006-07-27
ATE329597T1 (de) 2006-07-15
NO327358B1 (no) 2009-06-15
ES2266590T3 (es) 2007-03-01
DE60231068D1 (de) 2009-03-19
CN1330308C (zh) 2007-08-08
AU2006203428B2 (en) 2009-06-04
PT1427420E (pt) 2006-10-31

Similar Documents

Publication Publication Date Title
DE69842094D1 (de) Zusammensetzungen und Verfahren zur Behandlung primärer und metastatischer Erkrankungen mithilfe Arsentrioxid
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
ATE425749T1 (de) Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs
WO2002092854A3 (en) Genes expressed in breast cancer as prognostic and therapeutic targets
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
HK1068261A1 (en) Combinations comprisinga selective cyclooxygenase-2 inhibitor
WO2002012285A3 (en) The tumor suppressor car-1
HK1056692A1 (en) Proteins
DE60231068D1 (de) Die Verwendung von 4-Pyridylmethylphthalazinen zur Behandlung von Nierentumoren
BG108932A (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
MXPA04002407A (es) Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer.
ATE386748T1 (de) Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen
WO2007068449A3 (de) Molekulare marker für eine tumordiagnose und -therapie
ECSP044991A (es) Uso de 4-piridilmetil-ftalazinas para el tratamiento de cancer
WO2005048956A3 (en) Estradiol-related compounds and methods of use as anti-tumor agents
EP1438388A4 (de) Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen
TW200626150A (en) Use of Epothilones in the treatment of bone metastasis
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
UA67528A (en) Method for surgical treatment of thyroid cancer
RU2002113598A (ru) Способ лечения злокачественных опухолевых экссудативных плевритов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties